Mike Mensinger - 27 Feb 2026 Form 4 Insider Report for Beta Bionics, Inc. (BBNX)

Role
Chief Product Officer
Signature
/s/ Stephen Feider, Attorney-in-Fact
Issuer symbol
BBNX
Transactions as of
27 Feb 2026
Net transactions value
-$13,153
Form type
4
Filing time
03 Mar 2026, 18:45:11 UTC
Previous filing
07 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Mensinger Mike Chief Product Officer C/O BETA BIONICS, INC., 11 HUGHES, IRVINE /s/ Stephen Feider, Attorney-in-Fact 03 Mar 2026 0002048500
This filing has been restated, see here for the amended filing

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BBNX Common Stock Award $0 +109,105 +135% $0.000000 189,857 27 Feb 2026 Direct F1
transaction BBNX Common Stock Sale $13,153 -1,064 -0.56% $12.36 188,793 02 Mar 2026 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BBNX Employee Stock Option (right to buy) Award $0 +58,749 $0.000000 58,749 27 Feb 2026 Common Stock 58,749 $12.63 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan.
F2 The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.
F3 The weighted average sale price for the transaction reported was $12.3616 and the range of prices were between $12.20 and $12.55. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F4 The shares subject to this option shall vest in 36 equal monthly installments measured from March 1, 2026.